Evidence mapPaperPMID 41813658Full record

ReviewChinese medical journal2026

Therapy-induced remodeling of the tumor immune microenvironment: Mechanistic insights and implications for immunotherapy.

Dongping Chen, Ruiqi Wu, Zhengyu Liu, Yuan Wei, Dongming Kuang

Abstract readReview
In one paragraph

Review in Chinese medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dongping ChenGuangdong Province Key Laboratory of Pharmaceutical Functional Genes, MOE Key Laboratory of Gene Function and Regulation, School of Life Sciences, Sun Yat-sen University, Guangzhou, Guangdong 510275, China.
Ruiqi WuGuangdong Province Key Laboratory of Pharmaceutical Functional Genes, MOE Key Laboratory of Gene Function and Regulation, School of Life Sciences, Sun Yat-sen University, Guangzhou, Guangdong 510275, China.
Zhengyu LiuGuangdong Province Key Laboratory of Pharmaceutical Functional Genes, MOE Key Laboratory of Gene Function and Regulation, School of Life Sciences, Sun Yat-sen University, Guangzhou, Guangdong 510275, China.
Yuan WeiGuangdong Province Key Laboratory of Pharmaceutical Functional Genes, MOE Key Laboratory of Gene Function and Regulation, School of Life Sciences, Sun Yat-sen University, Guangzhou, Guangdong 510275, China.
Dongming KuangGuangdong Province Key Laboratory of Pharmaceutical Functional Genes, MOE Key Laboratory of Gene Function and Regulation, School of Life Sciences, Sun Yat-sen University, Guangzhou, Guangdong 510275, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractThe tumor immune microenvironment (TIME) plays a pivotal role in tumor initiation, progression, and therapeutic response, and is closely associated with long-term treatment efficacy. Notably, therapeutic interventions are not only influenced by the immune microenvironment but also actively remodel its cellular and molecular architecture. In recent years, advanced technologies such as single-cell sequencing, spatial transcriptomics, and other multi-omics approaches have provided unprecedented insights into the dynamic interplay between therapeutic modalities and the TIME, as well as the secondary microenvironmental changes that critically influence immunotherapy outcomes. In this review, we summarize therapy-induced remodeling of the TIME, elucidate the mechanisms by which these changes modulate immunotherapy responsiveness, and discuss potential strategies for therapeutic optimization. A deeper understanding of therapy-driven alterations in the TIME, empowered by emerging high-resolution technologies, will not only facilitate the monitoring and prediction of treatment efficacy but also guide the development of more precise and individualized combination treatment strategies.

Indexed as

ImmunotherapyNeoplasmsTumor MicroenvironmentAnimalsHumansImmune checkpoint blockadeImmune microenvironmentImmunotherapy resistanceTumor–immunity interactionTumor therapy

Identifiers

PMID41813658
PMCPMC13090054

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.